InvestorsHub Logo
Followers 91
Posts 5592
Boards Moderated 0
Alias Born 06/05/2008

Re: None

Monday, 01/08/2018 1:02:36 PM

Monday, January 08, 2018 1:02:36 PM

Post# of 8172
This stock is even MORE SPECULATIVE,

after today’s SEC filing. Right?

The contract manufacturer of FDA compliant CLRB products could could QUICKLY lever up clinical trial, and more importantly for the company, commercialized drug platform sales.

Or the outsourcing could mean CLRB is on the edge of oblivion. Think, Bluebird instead.

EITHER WAY, IT SEEMS GOOD MANAGEMENT TO BUY MORE TIME FOR CLINICAL TRIALS ON MULTIPLE CANCER TYPES AND TO BUY FASTER LIFT OFF TO HUGE PROFITS IF ONE OR MORE DRUG PLATFORMS IS SUCCESSFUL.

”...pays your money, and takes ‘yer chances...”, kids!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CLRB News